Jeffrey S. Weber, MD, PhD, deputy director of NYU Langone’s Perlmutter Cancer Center; Laura and Isaac Perlmutter Professor of Oncology in the Department of Medicine at NYU Grossman School of Medicine; and the 2016 OncLiveGiant of Cancer Care® in Melanoma, discusses research efforts examining neoadjuvant approaches in melanoma.
Video Reports
Dr. Glitza Oliva on Intrathecal/Intravenous Nivolumab in Metastatic Melanoma/Leptomeningeal Disease
Isabella C. Glitza Oliva, MD, PhD, MS, assistant professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the rationale for concurrent intrathecal (IT) and intravenous (IV) nivolumab (Opdivo) in patients with metastatic melanoma who have leptomeningeal disease.
The Importance of IMspire150 Data Is Questioned in Melanoma Treatment Landscape
Charles L. Sawyers, MD, internist and hematologic oncologist; chair of the Human Oncology and Pathogenesis Program; and Marie-Josée and Henry R. Kravis Chair at Memorial Sloan Kettering Cancer Center, discusses the value of atezolizumab (Tecentriq), cobimetinib (Cotellic), and vemurafenib (Zelboraf) in the melanoma treatment landscape.
Searching for Biomarkers to Better Guide Melanoma Therapy
Hello. I’m Dr Jeffrey Weber. I’m a medical oncologist at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center in New York City.